In this study, we show that UPEC are also targeted by the ATG16L1, LC3, and SQSTM1/p62 proteins. Our findings for UPEC, thus, resemble other studies on intracellular recognition of Salmonella enterica serovar Typhimurium, Shigella flexneri, and Listeria monocytogenes. We also find UPEC in double-membranous structures in transmission electron micrographs of infected bladders (Fig. 1) . The Virgin group had previously demonstrated that ATG16L1 HM mice develop intestinal abnormalities in Paneth cells. Our work shows that ATG16L1 deficiency induces multiple, baseline abnormalities in cellular components that UPEC encounter during infection. ATG16L1-deficient cells dramatically accumulate multivesicular bodies, lysosomes and the cytokine production. Thus, an ATG16L1 deficiency-induced hyperinflammatory response may help clear the infection by countering UPEC's ability to dampen innate immune responses.
It is important to determine if the protection we observed is ATG16L1-specific or represents a general effect of the autophagy pathway on UTI pathogenesis. The autophagy machinery comprises many essential proteins including ATG5, ATG7 and ATG12. We demonstrated that innate immune cell-specific knockdown of Atg5 induces a similar protective phenotype as that induced by ATG16L1 deficiency, suggesting that UPEC may hijack multiple autophagy components to colonize and persist in the urinary tract.
A polymorphism in ATG16L1 associated with CD can be found in up to 50% of individuals in certain populations. It is unclear why a seemingly unfavorable allelic variant of ATG16L1 would occur at such high frequency. One explanation is that the alleles were originally selected for a beneficial property such as protection against chronic or recurrent infectious diseases. Our results demonstrating that ATG16L1 mutation can confer protection against UTIs could explain why mutant alleles are unexpectedly frequent: protection against UTIs could be a mechanism to counter the negative selection imposed by the inflammation-promoting effects of the ATG16L1 mutation. A better understanding of the link between autophagy, latency, and inflammation could lead to therapeutic approaches, for example by targeting ATG16L1 or autophagy in general to treat recurrent UTI. Thus, the use of inhibitors of autophagy or ATG16L1 to eliminate latent bacterial reservoirs may have substantial clinical benefits to combat refractory and recurrent UTIs, because conventional antibiotics are unable to penetrate urothelial barriers to clear bacteria sequestered as QIRs.
